Skip to content

What exactly is harming pharmaceutical innovation in the UK

Sir, Behind Pfizer’s closure of its laboratories in Sandwich lies a bigger problem: the EU as a whole is not an attractive place to innovate. Increasingly stringent regulation provides a stultifying environment for innovation and entrepreneurship. Unless European policymakers can reverse this trend and not simply make worthless statements about encouraging the knowledge-based economy, we must all look forward to a future as an economic backwater.

Martin Livermore
Scientific Alliance, Cambridge

Letter published in The Times, 7 February 2011